NEURORECOVERY GETS ORPHAN DRUG DESIGNATION

摘要

Neurorecovery,Inc.(NRI),a biopharmaceutical company focused on treatments for peripheral neuropathies,has announced that its request for orphan drug designation of 4-Aminopyridine has been granted for treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome (GBS).